Page last updated: 2024-12-11
aldicarb sulfone
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
aldicarb sulfone: metabolite of aldicarb [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 9570093 |
| CHEMBL ID | 2138916 |
| CHEBI ID | 82051 |
| SCHEMBL ID | 23560 |
| MeSH ID | M0096613 |
Synonyms (67)
| Synonym |
|---|
| unii-il70ans043 |
| aldoxycarbe |
| il70ans043 , |
| 2-mesyl-2-methylpropionaldehyde o-methylcarbamoyloxime |
| 2-methyl-2-(methylsulfonyl)propanal o-(methylcarbamoyl)oxime |
| aldoxycarb |
| 2-methyl-2-(methylsulfonyl)propanal o-((methylamino)carbonyl)oxime |
| standak |
| epa pesticide chemical code 110801 |
| aldoxycarb [ansi:bsi:iso] |
| propanal, 2-methyl-2-(methylsulfonyl)-, o-((methylamino)carbonyl)oxime |
| brn 1971375 |
| 2-methyl-2-methylsulphonylpropionaldehyde o-methylcarbamoyloxime |
| 2-methyl-2-(methylsulphonyl)propionaldehyde o-(methylcarbamoyl)oxime |
| einecs 216-710-0 |
| propionaldehyde, 2-methyl-2-(methylsulfonyl)-, o-(methylcarbamoyl)oxime |
| ai3-29261 |
| propanal, 2-methyl-2-(methylsulfonyl)-, o-((methylamino)carbonyl) oxime |
| ent ai3-29261 |
| sulfocarb |
| ent 4.9 |
| uc-21865 |
| aldoxycarbe [iso-french] |
| caswell no. 011aa |
| rcra waste no. p203 |
| 2-methyl-2-(methylsulfonyl)propionaldehyde o-(methylcarbamoyl)oxime |
| aldicarb sulfone |
| propanal, 2-methyl-2-(methylsulfonyl)-, o-[(methylamino)carbonyl]oxime |
| NCGC00160630-01 |
| NCGC00160630-02 |
| 1646-88-4 |
| 2-methyl-2-(methylsulfonyl)propanal o-[(methylamino)carbonyl]oxime |
| NCGC00160630-03 |
| C18906 |
| cas-1646-88-4 |
| dtxsid6023862 , |
| NCGC00257229-01 |
| tox21_303266 |
| dtxcid503862 |
| NCGC00258890-01 |
| tox21_201338 |
| uces |
| yangdimiewei |
| temik sulfone |
| aldicarb-sulfone |
| AKOS015912931 |
| propanal, 2-methyl-2-(methylsulfonyl)-, o- ((methylamino)carbonyl) oxime |
| aldoxycarb [iso] |
| CS-3316 |
| HY-17530 |
| aldicarb (sulfone) |
| SCHEMBL23560 |
| CHEBI:82051 , |
| CHEMBL2138916 |
| (1e)-2-methyl-1-(([(methylamino)carbonyl]oxy)imino)-2-(methylsulfonyl)propane # |
| carbamic acid, methyl-, o-[[2-methyl-2-(methylsulfonyl)propylidene]amino] deriv. |
| YRRKLBAKDXSTNC-WEVVVXLNSA-N |
| [(e)-(2-methyl-2-methylsulfonylpropylidene)amino] n-methylcarbamate |
| J-519547 |
| aldicarb-sulfone, pestanal(r), analytical standard |
| J-010159 |
| 2-methyl-2-(methylsulfonyl)propanal-o-((methylamino)carbonyl)oxime |
| MS-23243 |
| (e)-(2-methanesulfonyl-2-methylpropylidene)amino n- methylcarbamate |
| DTXSID50859666 |
| aldicarb-d3sulfone |
| AKOS040759209 |
Research Excerpts
Compound-Compound Interactions
| Excerpt | Reference | Relevance |
|---|---|---|
| "The use of polypharmacy in the present day clinical therapy has made the identification of clinical drug-drug interaction risk an important aspect of drug development process." | ( In Vitro Drug-Drug Interaction Potential of Sulfoxide and/or Sulfone Metabolites of Albendazole, Triclabendazole , Aldicarb, Methiocarb, Montelukast and Ziprasidone. Giri, P; Giri, S; Gupta, L; Joshi, V; Naidu, S; Patel, N; Srinivas, NR, 2018) | 0.48 |
| "In vitro drug-drug interaction potential of test compounds was investigated in two stages; 1) assessment of CYP450 inhibition potential of test compounds using human liver microsomes (HLM); and 2) assessment of test compounds as substrate of Phase I enzymes; including CYP450, FMO, AO and MAO using HLM, recombinant human CYP enzymes (rhCYP), Human Liver Cytosol (HLC) and Human Liver Mitochondrial (HLMit)." | ( In Vitro Drug-Drug Interaction Potential of Sulfoxide and/or Sulfone Metabolites of Albendazole, Triclabendazole , Aldicarb, Methiocarb, Montelukast and Ziprasidone. Giri, P; Giri, S; Gupta, L; Joshi, V; Naidu, S; Patel, N; Srinivas, NR, 2018) | 0.48 |
| ", perpetrator and/or victim drug) to overcome any imminent risk of potential clinical drug-drug interaction when sulfoxide/sulfone metabolite(s) generating drugs are coadministered in therapy." | ( In Vitro Drug-Drug Interaction Potential of Sulfoxide and/or Sulfone Metabolites of Albendazole, Triclabendazole , Aldicarb, Methiocarb, Montelukast and Ziprasidone. Giri, P; Giri, S; Gupta, L; Joshi, V; Naidu, S; Patel, N; Srinivas, NR, 2018) | 0.48 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| sulfone | An organosulfur compound having the structure RS(=O)2R (R =/= H). |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Protein Targets (8)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| acetylcholinesterase | Homo sapiens (human) | Potency | 30.6485 | 0.0025 | 41.7960 | 15,848.9004 | AID1347395; AID1347397; AID1347398; AID1347399 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 76.8023 | 0.0030 | 41.6115 | 22,387.1992 | AID1159553 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 4.8459 | 0.0015 | 30.6073 | 15,848.9004 | AID1224849 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 35.4245 | 0.0002 | 29.3054 | 16,493.5996 | AID743069 |
| aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 68.8687 | 0.0007 | 23.0674 | 1,258.9301 | AID743122 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 61.3793 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
| heat shock protein beta-1 | Homo sapiens (human) | Potency | 59.8253 | 0.0420 | 27.3789 | 61.6448 | AID743210; AID743228 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 68.5896 | 0.0006 | 27.2152 | 1,122.0200 | AID651741 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Research
Studies (19)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 6 (31.58) | 18.7374 |
| 1990's | 6 (31.58) | 18.2507 |
| 2000's | 3 (15.79) | 29.6817 |
| 2010's | 4 (21.05) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 24.75
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (24.75) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 21 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||